February 2026 Options Now Available For Humana (HUM)

Humana (HUM) option ideas: the $255 put is bid $10.30 with HUM trading at $259.78, implying an effective purchase price of $244.70 and a 59% chance to expire worthless; the premium equates to a 4.04% return (33.51% annualized). The $265 call is bid $12.10 for a covered-call position, which would deliver a 6.67% total return if called at Feb 2026 and has a 50% chance to expire worthless, representing a 4.66% boost (38.64% annualized). Implied volatility is ~48% on the put and 50% on the call versus a 12‑month trailing volatility of 44%.

Analysis

Market structure: Option sellers and yield-seeking income strategies are the direct winners — selling the $255 put (collect $10.30, cost basis $244.70) or the $265 covered call (collect $12.10, 6.67% capped return) harvests a 4.0–4.7% one-period yield with ~50–59% OTM-expiry odds. Short-term supply/demand for HUM equity is unchanged, but the options market shows a 4–6pt IV premium versus realized volatility (48–50% vs 44%), signaling willing counterparties to pay for downside protection and creating a persistent short-gamma opportunity for premium sellers.

Risk assessment: Tail risks are regulatory (Medicare Advantage rate cuts of 2–5% could trigger 10–25% downside), enrollment shocks, or adverse claims/litigation that could widen IV and blow up short puts. Immediate (days) risk is IV spikes and assignment; short-term (weeks–months) risk centers on Feb 2026 expiry and guidance/earnings; long-term (quarters/years) depends on MA reimbursement trends and interest-rate driven discount rates.

Trade implications: For income-biased portfolios, cash-secured $255 puts or covered $265 calls are efficient ways to acquire HUM at ~2–3% strike delta with attractive theta; prefer small sizing (1–3% NAV) and use defined-risk spreads (credit put spreads or collars) to cap tail exposure. If IV compresses toward realized (<44%), sellers should take profits; if HUM trades below $244–240, be prepared to accept assignment or roll down conservatively.

Contrarian angles: The market understates policy tail risk — the high annualized YieldBoost (33–39%) is arithmetic and misleads on asymmetric downside. Historical parallels: MA reimbursement surprises have caused >20% moves; therefore naked put selling without hedges is underpriced risk. A cheap protection collar or 235/255 put spread would materially improve risk-adjusted returns.

Key Decisions for Investors

• Sell cash-secured HUM Feb 2026 $255 puts (collect $10.30) sized to 1–2% of portfolio NAV; set hard rule: if assigned, hold to target cost basis $244.70; if HUM < $240 before expiry, buy-to-close and redeploy into a 235/255 put debit spread to cap further downside.
• If already long HUM, sell Feb 2026 $265 covered calls (collect $12.10) to lock a 6.67% upside to $265; cap position size to 2–3% NAV and buy a Feb 2026 235/225 put vertical as insurance if position represents >2% NAV (limit cost to ~1% NAV).
• Avoid naked short-put exposure >3% NAV and instead implement defined-risk credit put spreads (sell 255 / buy 235) to convert attractive theta into capped downside; target net credit ≥$8.00 and close/roll if IV falls below realized (<=44%) or underlying rallies >8% (~>280).
• Rebalance healthcare exposure: trim overweight to UNH/large-cap insurers by 1–2% and redeploy into selective insured risk (HUM) via the above income strategies if your view expects stable MA rates; exit or hedge quickly if CMS signals a >2% MA rate reduction or HUM falls below $234 (≈10% drawdown trigger).